Patents by Inventor Jens Kvist Madsen

Jens Kvist Madsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11965039
    Abstract: Compstatin analogues having improved binding and complement-inhibiting activity as compared to the 13 amino acid compstatin peptide (ICVVQDWGHHRCT (cyclic C2-C12)) are described, in particular compstatin analogues that additionally possess useful physicochemical properties, such as increased solubility. These analogues include variants with an isoleucine residue at position 3 in place of the wild type valine residue, which provides compstatin peptides with improved binding and complement-inhibiting activity and also enables the introduction of other modifications, for example modifications that are capable of increasing solubility, such as the introduction of charged or polar amino acids at position 9 and/or the introduction of N- and/or C-terminal sequences.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: April 23, 2024
    Assignee: ZP SPV 3 K/S
    Inventors: Anne Pernille Tofteng Shelton, Jacob Ulrik Fog, Jens Kvist Madsen
  • Publication number: 20240076328
    Abstract: The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
    Type: Application
    Filed: July 14, 2023
    Publication date: March 7, 2024
    Inventors: Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
  • Patent number: 11780893
    Abstract: The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: October 10, 2023
    Assignee: Zealand Pharma A/S
    Inventors: Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
  • Publication number: 20230192770
    Abstract: Compstatin analogues having improved binding and complement-inhibiting activity as compared to the 13 amino acid compstatin peptide (ICVVQDWGHHRCT (cyclic C2-C12)) are described, in particular compstatin analogues that additionally possess useful physicochemical properties, such as increased solubility. These analogues include variants with an isoleucine residue at position 3 in place of the wild type valine residue, which provides compstatin peptides with improved binding and complement-inhibiting activity and also enables the introduction of other modifications, for example modifications that are capable of increasing solubility, such as the introduction of charged or polar amino acids at position 9 and/or the introduction of N- and/or C-terminal sequences.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 22, 2023
    Inventors: Anne Pernille Tofteng SHELTON, Jacob Ulrik FOG, Jens Kvist MADSEN
  • Publication number: 20220251151
    Abstract: The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
    Type: Application
    Filed: February 24, 2022
    Publication date: August 11, 2022
    Inventors: Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
  • Patent number: 11292820
    Abstract: The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: April 5, 2022
    Assignee: Zealand Pharma A/S
    Inventors: Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
  • Publication number: 20210380646
    Abstract: The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
    Type: Application
    Filed: June 23, 2021
    Publication date: December 9, 2021
    Inventors: Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen